SCHEMBL481069

SCHEMBL481069

CC(C)(C)[Si](C)(C)OCc1ccc(C(O)c2ccc(F)c(C#N)c2)cc1

nearest known ligand 0.34

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CACNA1H O95180 2/20 0.34
IDO1 P14902 2/20 0.33
FAAH O00519 1/20 0.33
APLNR P35414 1/20 0.32
BACE1 P56817 1/20 0.31
CYP11B1 P15538 1/20 0.31
CYP11B2 P19099 1/20 0.31
ADRB2 P07550 1/20 0.31
ADRB1 P08588 1/20 0.31
PTGDR2 Q9Y5Y4 1/20 0.31
TRPV3 Q8NET8 1/20 0.30
ALOX5 P09917 1/20 0.30
S1PR1 P21453 1/20 0.30
PLA2G7 Q13093 1/20 0.30
AR P10275 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL481055 0.85 ALDH1A1 (0.37) CACNA1HADRB2ADRB1ALOX5AR
SCHEMBL480243 0.81 FFAR1 (0.37) ALOX5
SCHEMBL480241 0.81 FFAR1 (0.37) ALOX5
SCHEMBL480962 0.77 KCNK3 (0.31)
SCHEMBL6928397 0.76 TRPV4 (0.42) CACNA1HCYP11B1CYP11B2
SCHEMBL3513144 0.72 PGR (0.42) PTGDR2
SCHEMBL31201807 0.72 IDO1 (0.41) IDO1BACE1
SCHEMBL8143451 0.71 SNCA (0.37) BACE1AR
SCHEMBL1004214 0.71 IDO1 (0.33) IDO1
SCHEMBL12840828 0.71 CYP4F2 (0.42) IDO1BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2441762-A1 Potentiators of Glutamate Receptors Eli Lilly and Company (US) 2012-04-18 EP disclosed
EP-1817301-B1 POTENTIATORS OF GLUTAMATE RECEPTORS LILLY CO ELI (US) 2012-02-01 EP disclosed
US-7816523-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2010-10-19 US disclosed
US-7803938-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2010-09-28 US disclosed
US-20090318481-A1 Potentiators Of Glutamate Receptors AICHER THOMAS DANIEL 2009-12-24 US disclosed
US-20090318483-A1 Potentiators Of Glutamate Receptors AICHER THOMAS DANIEL 2009-12-24 US disclosed
US-7598423-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2009-10-06 US disclosed
US-20080139505-A1 Potentiators Of Glutamate Receptors ARRAY BIOPHARMA, INC. 2008-06-12 US disclosed
EP-1817301-A1 POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2007-08-15 EP disclosed
WO-2006057870-A1 POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2006-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139505-A1 Potentiators Of Glutamate Receptors GRM1, GRIN1, GRM2 CACNA1H 350/4885IDO1 2210/4885FAAH 1561/4885
US-20090318481-A1 Potentiators Of Glutamate Receptors GRIK1, GRIK2, GRIK4 CACNA1H 261/4885IDO1 3036/4885FAAH 691/4885
US-20090318483-A1 Potentiators Of Glutamate Receptors GRIK1, GRIK2, GRIK4 CACNA1H 261/4885IDO1 3036/4885FAAH 691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.